Chromosome Condensation 1-Like (Chc1L) Is a Novel Tumor Suppressor Involved in Development of Histiocyte-Rich Neoplasms.

PLoS One

Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; Department of Medicine & Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Physiology, University of Toronto, Toronto, Ontario, Canada.

Published: May 2016

Human chromosomal region 13q14 is a deletion hotspot in prostate cancer, multiple myeloma, and chronic lymphocytic leukemia. This region is believed to host multiple tumor suppressors. Chromosome Condensation 1-like (CHC1L) is located at 13q14, and found within the smallest common region of loss of heterozygosity in prostate cancer. Decreased expression of CHC1L is linked to pathogenesis and progression of both prostate cancer and multiple myeloma. However, there is no direct evidence for CHC1L's putative tumor suppressing role in current literature. Presently, we describe the generation and characterization of Chc1L knockout mice. Chc1L-/- mice do not develop cancer at a young age, but bone marrow and spleen cells from 8-12 week-old mice display an exaggerated proliferative response. By approximately two years of age, knockout and heterozygote mice have a markedly increased incidence of tumorigenesis compared to wild-type controls, with tumors occurring mainly in the spleen, mesenteric lymph nodes, liver and intestinal tract. Histopathological analysis found that most heterozygote and knockout mice succumb to either Histiocytic Sarcoma or Histiocyte-Associated Lymphoma. Our study suggests that Chc1L is involved in suppression of these two histiocyte-rich neoplasms in mice and supports clinical data suggesting that CHC1L loss of function is an important step in the pathogenesis of cancers containing 13q14 deletion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546397PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135755PLOS

Publication Analysis

Top Keywords

prostate cancer
12
chromosome condensation
8
condensation 1-like
8
1-like chc1l
8
histiocyte-rich neoplasms
8
13q14 deletion
8
cancer multiple
8
multiple myeloma
8
knockout mice
8
chc1l
6

Similar Publications

Introduction: Macrophages exhibit marked phenotypic heterogeneity within and across disease states, with lipid metabolic reprogramming contributing to macrophage activation and heterogeneity. Chronic inflammation has been observed in human benign prostatic hyperplasia (BPH) tissues, however macrophage activation states and their contributions to this hyperplastic disease have not been defined. We postulated that a shift in macrophage phenotypes with increasing prostate size could involve metabolic alterations resulting in prostatic epithelial or stromal hyperplasia.

View Article and Find Full Text PDF

Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.

Front Immunol

January 2025

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic and therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively identifies tumors and metastatic lymph nodes for imaging purposes, while -PSMA-617 (Pluvicto) has received FDA approval for treating metastatic castration-resistant PCa (mCRPC).

View Article and Find Full Text PDF

Background And Purpose: This study assessed the treatment time of online adaptive (i.e. Adapt-to-Shape, ATS) and virtual couch shift (i.

View Article and Find Full Text PDF

Background And Aims: Even though aging is a known risk factor for prostate cancer incidence and mortality, there has been an increase in incidence among young men since the late 1980s with notably lower survival rates than those among older men. However, there is insufficient knowledge about recent trends in the incidence and survival of this disease.

Methods: We analyzed prostatic cancer incidence trends in men under 50 from 1975 to 2020 using Surveillance, Epidemiology, and End Results (SEER) 8 registries data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!